What happened with IRMD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
iRadimed Corporation helps hospitals give intravenous fluids and monitor patients inside magnetic resonance imaging (MRI) scanner rooms. Its MRidium infusion pumps and 3880 vital signs monitor use non-magnetic components to operate around the scanner’s strong magnetic field. These two product lines underpin the business, and device sales supply most revenue. Each use of a pump requires a proprietary disposable IV tubing set, making disposables the next-largest revenue source; maintenance and services contribute less.
Most revenue comes from the United States, where iRadimed sells directly to hospitals and acute care facilities. Hospital-network and group-purchasing contracts help it reach member hospitals, so access to these purchasing arrangements matters. Independent distributors handle sales outside the United States.
The business also depends on obtaining critical components from outside suppliers, some of which are single sources. Certain proprietary components cannot be replaced with another supplier’s parts without regulatory approval. Its devices require FDA clearance for U.S. sale, and continued sales depend on meeting manufacturing and other regulatory requirements.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Philips owns Invivo Research, the market leader IRadimed identifies as its dominant rival in selling hospitals monitors that track patients’ vital signs during MRI scans. Watch Invivo’s MRI-monitoring business for competitive pressure on IRadimed’s monitoring-system sales.
GE HealthCare competes with IRadimed to sell hospitals monitors that track patients’ vital signs during MRI scans, and established customer relationships can make hospitals reluctant to switch to IRadimed’s newer 3880 monitor. Watch whether hospitals stay with established systems or adopt the 3880.
ICU Medical’s conventional infusion pumps and IV sets offer hospitals an alternative to IRadimed’s MRI-specific pumps: they can place a conventional pump outside the scanning room and use extension tubing, a workaround IRadimed says adds patient-safety risks. That choice matters beyond the pump sale, because every use of an IRadimed MRI-compatible pump requires its proprietary disposable tubing set.
GE HealthCare Technologies Inc. earningsGEHC
GE HealthCare’s report will show demand for its MRI vital-sign monitors, revealing the competitive pressure iRadimed faces as it seeks hospital orders for the 3880.
Watch demand for GE HealthCare’s monitoring systems. Resilient demand would suggest hospitals are sticking with established systems, making it harder for iRadimed to win relationships for the 3880. Weaker demand would suggest less competitive pressure, but would not prove hospitals are switching to iRadimed.
iRadimed Corporation earningsThis company
iRadimed sells MRI-compatible pumps, monitors and related supplies to hospitals; this report will show whether device sales are bringing recurring revenue from the proprietary tubing each pump use requires.
Read MRI-compatible pump and monitor sales alongside disposable revenue. Growth in both would show hospitals are buying the devices and continuing to use them. If devices grow but disposables lag, use or sales mix may be weakening; if both fall back, demand across the business is softening.
